Study on Human T Leukemia-Lymphoma Cell Lines by the Second International Workshop Monoclonal Antibodies of the T Cell Protocol

The First International Workshop and Conference on Human Leukocyte Differentiation Antigens was held in November, 1982 in Paris, France; this conference provided means and emphasized the need for a worldwide collaboration in the study of human leukocyte antigens (1). Among numerous impacts of the Workshop, uses of murine monoclonal hybridoma antibodies (mAbs) and of leukemia-lymphoma cell lines as consistent cells were amply recognized (1,2). Limitations and difficulties associated with the use of both mAbs and leukemia-lymphoma cell lines have already been documented (3). Large numbers of growth factor-independent human leukemia-lymphoma cell lines of diverse cell lineages have continued to play significant roles in the research of leukocyte differentiation antigens (4). During the First Workshop 165 coded mAbs were tested on 30 leukemia-lymphoma cell lines (10 T, 10 B, and 10 myelomonocytic or non-T/non-B cell lines) (5).